| --- | --- | --- | --- | --- | |-------|----------------------------------|-------|-------|-------| | | | | | | | | Proteins by Design | ® | | | | | Antibody & Cytokine Therapeutics | | | | Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's deve ...

Xencor, Inc. (NASDAQ:XNCR) Q1 2021 Results Conference Call May 5, 2021 4:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Kuch - Chief Financial Officer John Desjarlais - Chief Scientific Officer Conference Call Participants Ted Tenthoff - Piper Sandler Mara Goldstein - Mizuho Securities Peter Lawson - Barclays Li Wang Watsek - Cantor Etzer Darout - Guggenheim Tom Shrader - BTIG Zhiqiang Sh ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36182 Xencor, Inc. (Exact name of registrant as specified in its charter) Delaware 20-16225 ...

Xencor Inc (NASDAQ:XNCR) Q4 2020 Earnings Conference Call February 23, 2021 4:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Kuch - Chief Financial Officer John Desjarlais - Chief Scientific Officer Conference Call Participants Ted Tenthoff - Piper Sandler Mara Goldstein - Mizuho Securities Gregory Renza - RBC Capital Markets Alethia Young - Cantor Fitzgerald Jonathan Chang - SVB Leerink ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36182 Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation or Or ...

Financial Data and Key Metrics Changes - As of September 30, 2020, cash, cash equivalents, and marketable securities totaled $582.9 million, down from $601.3 million at December 31, 2019, reflecting cash used for operating activities [31] - Total revenue for Q3 2020 was $35.4 million, compared to $21.8 million for the same period in 2019, driven by milestone revenue from MorphoSys and licensing revenue from Omeros [32] - Total revenue for the nine months ended September 30, 2020, was $80.8 million, down from $153.2 million for the same period in 2019, primarily due to higher collaboration licensing revenue in 2019 [33] - Research and development expenditures for Q3 2020 were $44.5 million, up from $29.8 million in Q3 2019, reflecting increased spending on clinical programs [34] - Net loss for Q3 2020 was $12.6 million, or $0.22 per share, compared to a net loss of $10.2 million, or $0.18 per share, for the same period in 2019 [37] - For the nine months ended September 30, 2020, net loss was $55.6 million, or $0.97 per share, compared to net income of $53.8 million, or $0.92 per share, for the same period in 2019 [38] Business Line Data and Key Metrics Changes - The company is currently running six Phase I clinical studies evaluating XmAb bispecific antibodies, with a focus on oncology treatments [9] - The autoimmune IL-2 Fc program, XmAb27564, is on track for a Phase I study initiation in early 2021 [12][23] - The company has 12 ongoing partnerships for XmAb technology, resulting in two marketed products: Alexion's ULTOMIRIS and MorphoSys' Monjuvi [26] Market Data and Key Metrics Changes - The COVID-19 pandemic did not significantly disrupt patient enrollment in ongoing clinical studies, although there were critical shortages of materials affecting manufacturing processes [11] - Partnerships with companies like Genentech and Omeros continue to generate revenue without significant COVID-19 impacts [24] Company Strategy and Development Direction - The company is focusing on expanding its XmAb bispecific platform to create antibodies that bind multiple targets and engineer cytokines optimized for therapeutic use [9] - Partnerships are a core part of the business model, generating payments from licensing XmAb technologies and royalties from approved products [24] - The company is exploring opportunities to develop vibecotamab in patients with lower baseline leukemic disease burden [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing clinical programs and the potential for advancing multiple assets based on emerging proof-of-concept data [89] - The company expects to have sufficient cash to fund R&D programs and operations into 2024, projecting to end 2020 with between $525 million and $575 million in cash [39] Other Important Information - The company is maintaining remote work requirements for non-laboratory employees while ensuring on-site safety measures for those working in labs [12] - The company is developing a suite of cytokines engineered with XmAb bispecific Fc domains to improve their properties and drug-like characteristics [21] Q&A Session Summary Question: Next steps for CD123 for AML - Management indicated that they have restrictions due to the partnership with Novartis but noted that they observed more activity in patients with lower disease burdens [41][44] Question: Bar for AML in this population - Management stated that the populations possible with the agent vary, and they have good ideas about the bar without disclosing specifics [46] Question: Confidence in tolerability of 20717 - Management discussed the design of the molecule, which requires cooperative binding for strong binding, and noted that the tolerability profile is encouraging [50][54] Question: Planned studies for plamotamab - Management confirmed that Phase II studies are planned for relapsed refractory DLBCL, with more details to come [58] Question: Differences in patient characteristics for vibecotamab - Management indicated that there have not been significant changes to inclusion/exclusion criteria, so no major shifts in demographics are expected [72]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36182 Xencor, Inc. (Exact name of registrant as specified in its charter) Delaware 20-1 ...

Antibodies by Design™ XmAb® Antibody Therapeutics Corporate Overview August 2020 Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; expected use of cash resources; the timing and resu ...

Xencor Inc (NASDAQ:XNCR) Q2 2020 Results Conference Call August 4, 2020 4:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Desjarlais - Chief Scientific Officer John Kuch - Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler & Co. Jonathan Chang - SVB Leerink Mara Goldstein - Mizuho Securities Arlinda Lee - Canaccord Genuity Tom Shrader - BTIG Peter Lawso ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36182 Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 20-1622502 (State or Other Jurisdiction of Incorporation or Organization) 111 West Lemon Avenue, Monrovia, CA 91016 (Address of Principal Executive Offices) (Zip Code) (626) 305-5900 ☒ QUARTERLY REPORT ...